Volume 21, Issue 2 pp. 133-138
Case Report

A second unrelated bone marrow transplant: successful quantitative monitoring of mixed chimerism using a highly discriminative PCR-STR system

I. W. Blau

I. W. Blau

Clinic for Bone Marrow Transplantation and Haematology/Oncology, Idar-Oberstein and

Search for more papers by this author
N. Basara

N. Basara

Clinic for Bone Marrow Transplantation and Haematology/Oncology, Idar-Oberstein and

Search for more papers by this author
A. Serr

A. Serr

Clinic for Bone Marrow Transplantation and Haematology/Oncology, Idar-Oberstein and

Search for more papers by this author
C. Seidl

C. Seidl

Institute for Transfusion Medicine and Immunohematology, Red Cross Blood Donor Service Hessen, Frankfurt/Main, Germany

Search for more papers by this author
E. Seifried

E. Seifried

Institute for Transfusion Medicine and Immunohematology, Red Cross Blood Donor Service Hessen, Frankfurt/Main, Germany

Search for more papers by this author
M. Fuchs

M. Fuchs

Institute for Transfusion Medicine and Immunohematology, Red Cross Blood Donor Service Hessen, Frankfurt/Main, Germany

Search for more papers by this author
M. Bischoff

M. Bischoff

Clinic for Bone Marrow Transplantation and Haematology/Oncology, Idar-Oberstein and

Search for more papers by this author
E. Roemer

E. Roemer

Clinic for Bone Marrow Transplantation and Haematology/Oncology, Idar-Oberstein and

Search for more papers by this author
A. A. Fauser

A. A. Fauser

Clinic for Bone Marrow Transplantation and Haematology/Oncology, Idar-Oberstein and

Search for more papers by this author
First published: 24 December 2001
Citations: 14
Dr I.W. Blau, Clinic of Bone Marrow Transplantation and Hematology/Oncology Dr Ottmar-Kohler Strasse 2, 55743 Idar Oberstein, Germany.

Abstract

A second bone marrow transplant (BMT) might be considered as an option in patients with leukaemia with graft failure after BMT. We report the successful treatment of a patient with graft failure by a second stem cell transplant from another unrelated donor. We evaluated the usefulness of an unrelated donor as the source of the second BMT in this clinical setting. In addition to this, a penta PCR-STR system was tested and shown to be sensitive for monitoring of marrow engraftment. The conditioning regimen for the first transplantation consisted of busulfan and cyclophosphamide while anti-thymocyte globulin and CY were used for the second BMT. The patient successfully engrafted at day + 11 after second BMT.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.